Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: A study protocol of the OPTIMA-AF trial

Yohei Sotomi, Ken Kozuma, Kosuke Kashiwabara, Yoshiharu Higuchi, Kenji Ando, Yoshihiro Morino, Junya Ako, Kengo Tanabe, Takashi Muramatsu, Gaku Nakazawa, Shungo Hikoso, Yasushi Sakata

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Introduction The optimal antithrombotic strategy for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) is uncertain. For patients with non-AF, many trials are now evaluating short 1-month dual antiplatelet therapy. In patients with AF undergoing PCI, in contrast, short dual therapy (P2Y 12 inhibitor +direct oral anticoagulant (DOAC)) has not yet been evaluated. Methods and analysis The OPTIMA-AF trial (OPTIMAl antiplatelet therapy in combination with direct oral anticoagulants in patients with non-valvular Atrial Fibrillation undergoing percutaneous coronary intervention with everolimus-eluting stent) is an investigator-initiated, open-label, nationwide, multicentre, prospective, randomised controlled trial. The primary objective is to compare the efficacy and safety of short dual therapy (1-month DOAC +P2Y 12 inhibitor followed by DOAC monotherapy) against long dual therapy (12-month DOAC +P2Y 12 inhibitor followed by DOAC monotherapy) in the treatment of AF subjects undergoing PCI. The primary efficacy endpoint is a composite of death or thromboembolic events (myocardial infarction, definite stent thrombosis, stroke or systemic embolism) at 365 days; and the primary safety endpoint is bleeding (International Society on Thrombosis and Haemostasis major or clinically relevant non-major bleeding) at 365 days. This trial is intended to show the non-inferiority of short dual therapy versus long dual therapy in terms of the primary efficacy endpoint and show superiority in terms of the primary safety endpoint. A total of 1090 subjects will be randomised in a 1:1 ratio at approximately 60 sites. Ethics and dissemination This study received approval from the Certified Review Board of Osaka University (a certified research ethics committee by the Japanese Clinical Research Act). The findings will be disseminated through peer-reviewed publications and conference presentations. Trial registration number Japan Registry of Clinical Trials: jRCTs051190053; Pre-results.

Original languageEnglish
Article numbere048354
JournalBMJ Open
Volume11
Issue number12
DOIs
Publication statusPublished - 01-12-2021

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: A study protocol of the OPTIMA-AF trial'. Together they form a unique fingerprint.

Cite this